Hansoh Pharma's Trop-2 ADC HS-20105 Granted IND Approval for Advanced Solid Tumors

On September 25, Hansoh Pharma issued an announcement stating that HS-20105, a Trop-2 targeted ADC drug independently developed by its subsidiaries Shanghai Hansoh BioMedical Co., Ltd. and Changzhou Humon Pharmaceutical Co., Ltd., has been approved for clinical trials. It is intended for the treatment of advanced solid tumors, with specific indications to be determined after clinical trials.

HS-20105 is an antibody-drug conjugate (ADC) formed by conjugating a DNA topoisomerase I inhibitor to a humanized anti-Trop-2 monoclonal antibody of the IgG1 subtype through a protease-cleavable linker.

Currently, globally, only one Trop-2 ADC has been approved for marketing, namely Gilead's Sacituzumab Govitecan. In the same赛道, Merck/Kelun Biotech's SKB264 and AstraZeneca/Daiichi Sankyo's Dato-DXd are in the relatively advanced Phase III clinical stage.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. Medicine Cube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Medcube Reader Survey Questionnaire

Thank you for your companionship. Looking forward to your feedback.

Scan the QR code to provide valuable suggestions